BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 20, 2018--
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it has commenced an underwritten public offering of
up to $150,000,000 of shares of its common stock. All of the shares to
be sold in the offering will be offered by Aimmune. In addition, Aimmune
expects to grant the underwriters of the offering a 30-day option to
purchase up to an additional $22,500,000 of shares of common stock at
the public offering price, less underwriting discounts and commissions.
The offering is subject to market and other conditions, and there can be
no assurance as to whether or when the offering may be completed, or as
to the actual size or terms of the offering.
Aimmune currently expects to use the net proceeds from this offering to
fund its ongoing clinical development of AR101, an investigational
biologic for the treatment of patients with peanut allergy, regulatory
activities related to the potential filing of a Biologics License
Application and a Marketing Authorization Application for AR101,
preparation for potential commercialization of AR101, research and
development of additional CODITTM product candidates, and for
general corporate purposes.
BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper Jaffray & Co. are
acting as joint bookrunning managers for the offering. Credit Suisse and
RBC Capital Markets are also acting as bookrunning managers.
A registration statement relating to the securities being sold in this
offering was filed with the Securities and Exchange Commission on
February 20, 2018, and was automatically declared effective upon filing.
The offering of these securities is being made only by means of a
prospectus, copies of which may be obtained from: BofA Merrill Lynch,
NC1-004-03, 200 North College Street, 3rd floor, Charlotte, NC
28255-0001, Attention: Prospectus Department, email: email@example.com;
or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park
Avenue, 6th Floor, New York, NY 10022; email: firstname.lastname@example.org;
or from Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at
800-747-3924 or email at email@example.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for potentially life-threatening food
allergies. The company’s Characterized Oral Desensitization
ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels
of protection by desensitizing patients with defined, precise amounts of
key allergens. Aimmune’s first investigational biologic product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4–17 years of age and is currently being
evaluated in Phase 3 clinical trials.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006569/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,